Next 10 |
Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings ( SWVL ) ...
Commercial-stage biopharma, Cara Therapeutics ( NASDAQ: CARA ) announced on Thursday that the company’s lead product difelikefalin reached the primary endpoint in a Phase 2 trial designed to evaluate it in pruritus in patients with notalgia paresthetica (NP). NP is ...
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
Since I wrote my bullish call on Cara Therapeutics, the shares have absolutely collapsed. I thought I'd revisit the name again to see if I should add, hold, or sell. The company reported earnings, and the same trend persists: the company sells more, and loses more, and this trend need...
Amarin Corporation (NASDAQ:AMRN) has appointed Tom Reilly as Chief Financial Officer, effective June 20, 2022, following the resignation of Michael W. Kalb. Michael is stepping down to pursue other interests. Most recently, Tom Reilly served as Chief Financial Officer for Cara Thera...
Gainers: Fanhua (FANH) +7%. Ocular Therapeutix (OCUL) +5%. ThredUp (TDUP) +5%. Cara Therapeutics (CARA) +3%. LegalZoom.com (LZ) +3%. Losers: Eton Pharmaceuticals (ETON) -21%. Allakos (ALLK) -7%. Accolade (ACCD) -5%. Sono Group (SEV) -5%. FTC Solar (FTCI) -4%. For furth...
Shares of Cara Therapeutics (NASDAQ:CARA) have added 23.4% to $9.20 in Tuesday afternoon trading, after the biopharmaceutical company reported Q1 2022 earnings that beat estimates. CARA posted Q1 GAAP EPS of -$0.52 which beat estimates by $0.10, and revenue of $4.79M which beat by $...
Cara Therapeutics, Inc. (CARA) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Chris Posner - President & Chief Executive Officer Tom Reilly - Chief Financial Officer Joana Goncalves - Chief Medical Officer...
Cara Therapeutics press release (NASDAQ:CARA): Q1 GAAP EPS of -$0.52 beats by $0.10. Revenue of $4.79M (+146.9% Y/Y) beats by $2.53M. Cash, cash equivalents and marketable securities at March 31, 2022 totaled $209.6 million compared to $236.8 million at December 31, 2021. Cara expects that it...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...